Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.
NCT00970229
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
19
Enrollment
OTHER
Sponsor class
Conditions
Parkinson Disease
Huntington Disease
Interventions
DRUG:
[123I]MNI-420
Sponsor
Institute for Neurodegenerative Disorders